• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin

    2021-05-19 14:03:42YuanJiMaLingYaoDuLiBoYanJuanLiaoXingChengWuWeiXieHongTang

    Yuan-Ji Ma,Ling-Yao Du,Li-Bo Yan,Juan Liao,Xing Cheng,Wu-Wei Xie,Hong Tang

    Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, China

    Keywords:Hepatitis C virus Sustained virological response Hepatocellular carcinoma

    ABSTRACT Background: The progress of liver diseases may not stop after viral eradication.This study aimed to provide data on long-term prognosis of patients with hepatitis C virus (HCV) infection who underwent pegylated interferon plus ribavirin (PR) regimen and achieved a sustained virological response 24 weeks post-treatment (SVR24).Methods: Responders to the PR regimen in our hospital from January 2011 to June 2014 were enrolled and prospectively followed up.Baseline characteristics were profiled.The incidence of hepatocellular carcinoma (HCC),progression of liver disease (increase in liver stiffness or occurrence of decompensated complication),and HCV recurrence was all monitored.The accumulative and annualized incidence rates(AIRs) of these adverse events were analyzed,and the risk factors were also examined.Results: In total,151 patients reached a median follow-up time of 103 weeks.Among them,two had an incidence of HCC during the surveillance with AIR of 0.68% (95% CI:0.00-1.63%).Six patients showed progression of liver disease with AIR of 2.05% (95% CI:0.42%-3.68%).Three patients who had risky behaviors encountered HCV reinfection.The cirrhotic patients faced higher risk of poor prognosis than non-cirrhotic patients,including HCC and progression of liver disease (AIR:6.17% vs.1.42%,P=0.039).Conclusions: The incidence of HCC and progression of liver disease was evident in PR responders during the long-term follow-up period,but the risk level was low.Cirrhotic responders were more vulnerable to develop HCC post SVR24 compared with non-cirrhotic ones.HCV recurrence was rare in responders with SVR24 who had corrected their risky behaviors.

    Introduction

    Pegylated interferon (Peg-IFN) plus ribavirin (PR) regimen used to be the standard therapeutic option for patients with chronic hepatitis C (CHC) in China since the beginning of this century [1].A previous study reported that the therapeutic efficacy of the PR regimen in patients with IL-28 CC genotype reached 80% or more [2].Most patients could achieve a sustained virological response (SVR) if a full therapeutic course was completed [3].

    However,the progression of liver disease may not stop after viral eradication,especially in patients with advanced cirrhosis.A previous study also revealed that even in non-cirrhotic patients,risks still existed after an SVR was achieved [4].Therefore,patients with viral eradication are recommended to receive longterm hepatocellular carcinoma (HCC) surveillance.However,the data of long-term follow-up in treated Chinese patients are still lacking.Further investigations are needed in both cirrhotic and non-cirrhotic patients.

    In this study,we reported the long-term prognosis of hepatitis C virus (HCV)-infected patients who received a full course of PR treatment and achieved SVR 24 weeks post-treatment (SVR24).

    Methods

    Study subjects

    All subjects who were diagnosed with CHC through a positive serum HCV RNA test and had received PR regimens from January 2011 to June 2014,were recorded and prospectively followed up.The subjects who completed a full therapeutic course and achieved an SVR24 were screened.Of the PR regimens,Peg-IFNα?2a or Peg-IFNα?2b was prescribed according to physical condition and health insurance of patients and availability of drugs.Sanger sequencing with PCR kit (Daan gene,Guangzhou,China)was applied and performed on ABI9700 (Life technologies,Carlsbad,USA) to identify HCV genotype.The SVR24 was defined if the high-precision HCV RNA test was negative through“The COBASR○AmpliPrep/COBASR○ TaqManR○ HCV Test”(Roche Diagnostics,GmbH,Mannheim,Germany) 24 weeks after treatment.Then,a long-term follow-up was conducted every year to learn their prognosis.Written informed consent (Version:2016.03) was acquired from all the patients.This study was approved by the Ethics Committee of West China Hospital [Authorization Number:2016 annual audit (91)].

    Fig.1.The study flow diagram to identify the cohort of long-term follow-up.SVR24:sustained virological response 24 weeks post treatment.

    Study endpoints

    The primary endpoint of this study was the long-term prognosis,including the incidence of HCC,the progression of liver disease(increase in liver stiffness or occurrence of decompensated complication),and HCV recurrence.The secondary endpoint was the difference in long-term prognosis between cirrhotic and non-cirrhotic patients.

    HCC was identified by yearly follow-up and tracing the source medical record.The first recorded date of HCC after SVR was considered the incident date.The liver stiffness was evaluated through either transient elastography using FibroScanR○or aspartate aminotransferase (AST)-to-platelet ratio index (APRI) score every year.The increase of FibroScanR○value from<12.4 kPa to>12.4 kPa or APRI from<2.0 to>2.0 was defined as an“increase in liver stiffness”[5].The increase in liver stiffness or the occurrence of cirrhosis-related complications other than HCC was defined as progression of liver disease.

    The follow-up ended when HCC was diagnosed,the patient died,or HCV RNA was positive.Data were collected until June 1,2017.

    Statistical analysis

    Baseline characteristics were analyzed in all cohorts to give a profile of CHC patients.The incidence of HCC,progression of liver disease,and HCV recurrence were compared between cirrhotic and non-cirrhotic patients.

    All data were analyzed using SPSS 18.0 (IBM SPSS Statistics,Chicago,IL,USA).The enumeration data were expressed as percentages and analyzed with the Chi-square test or Fisher’s exact test.The measurement data were analyzed for normality first.Normally-distributed data were expressed as mean ± standard deviation (SD) and analyzed with the Student’st-test,while nonnormally-distributed data were expressed as median (interquartile range,IQR) and analyzed with theUtest.A comparison between normally-distributed data and non-normally-distributed data was also conducted via theUtest.The relationship between different indicators was analyzed with correlation or regression analysis.APvalue<0.05 was considered statistically significant.

    Results

    Baseline characteristics of the patients

    Among 220 subjects,41 encountered relapse before achieving SVR24,28 lost to follow up,151 finished long-term follow up (Fig.1).The baseline characteristics of the 151 subjects were shown in Table 1 .Half of them were males.The average age at the initial treatment was 46.0 ± 13.3 years.They were infected by various genotypes of HCV.Among them,genotype 1b HCV was the majority (76.2%),and the viral genotype could not be identified in two patients.The median baseline viral load was 6.02 (IQR 4.86–6.66) logIU/mL,while the baseline alanine aminotransferase (ALT)was 54 (IQR 31–109) IU/L.Although alpha-fetoprotein (AFP) level was elevated in 21.9% of the patients,HCC was excluded through abdominal ultrasound.

    All patients were divided into two groups according to their liver stiffness,which was measured by FibroScanR○,or elevated APRI (APRI>2.0).Among them,38 patients (25.2%) were identified as cirrhotics (Table 1).The sex distribution in the two groups showed no significant difference (55.3% vs.50.4%,P=0.607).The cirrhotic patients were significantly older (51.4 ± 8.2 vs.44.1 ± 14.2 years,P<0.001).The proportion of genotype 1b in cirrhotic patients was significantly higher than that in non-cirrhotic patients (92.1% vs.70.8%,P=0.030).ALT,antinuclear antibody,AFP,platelet and neutrophil levels were also significantly different between the two groups (Table 1).

    Table 1 Baseline characteristics of the study cohort.

    Table 2 The annualized incidence rate (AIR) of adverse events in patients under long-term surveillance after SVR24.

    Table 3 Possible risk factors related to HCV reinfection.

    Long-term follow-up

    Of the recorded 151 patients,38 were cirrhotic responders and 113 were non-cirrhotic ones.The median follow-up time was 103(IQR 77–126) weeks.Two patients had incident HCC during the long-term surveillance.The annualized incidence rate (AIR) of HCC in our cohort was 0.68% (95% CI:0.00 ?1.63%) (Table 2).Six patients showed progression of liver disease with AIR of 2.05% (95%CI:0.42% ?3.68%).Three patients encountered HCV reinfection with AIR of 1.02% (95% CI:0.00–2.18%).

    The AIRs of HCC and progression of liver disease were 0.66%and 1.32% in the patients under the first follow-up year after SVR24,respectively.In the patients under the second follow-up year after SVR24,the AIRs of HCC and progression of liver disease were both 0.93%.In addition,no incidence of HCC was observed in patients followed up for more than 3 years.It may imply that after SVR24 was achieved,the patients would be at a relatively low risk of HCC (Table 2).

    According to a previous study,HCV relapse was rare after successful SVR achievement [6].In our cohort,we observed no relapse but 3 cases of HCV reinfection in the long-term follow-up.We retrospectively reviewed the baseline characteristics and therapeutic course in these three patients and found that all had the risk factors of reinfection,among which one had hemophilia and multiple blood transfusions,one had drug injection,and one had risky sexual behavior (Table 3).

    Table 4 The annualized incidence rate (AIR) of liver deterioration in cirrhotic patients and non-cirrhotic patients.

    As no HCV relapse was found,only the incidence of HCC and progression of liver disease were calculated respectively in cirrhotic and non-cirrhotic patients (Table 4).In addition,we analyzed AIR to balance the difference of follow-up period in the two groups.The AIR of HCC was low in both groups without significant difference (1.24% vs.0.47%,P=0.447).However,the progression of liver disease was different,with marginal significance (4.94% vs.0.94%,P=0.051).Moreover,when the incidence of HCC and progression of liver disease were analyzed together,patients in the cirrhotic groups were more likely to encounter liver deterioration(HCC or progression of liver disease) even after HCV elimination(6.17% vs.1.42%,P=0.039;Table 4).These results implied that although the incidence was low after SVR,the long-term prognosis was still different between cirrhotic and non-cirrhotic patients.

    Discussion

    HCV-related liver cirrhosis occurs at a rate of 2% ?30% depending on age,sex,and transmission route if HCV infection is left untreated [7,8].In addition,once liver cirrhosis is confirmed,the morbidity of the decompensated cirrhosis is 3% ?4% yearly and that of HCC is 2% ?4% yearly [9].Both statuses are associated with high mortality.Antiviral therapy is aimed to eradicate HCV,ease liver damage,and stop disease progression.

    However,eradication of the virus sometimes did not result in a real cure of the disease,and the patients faced a risk of disease deterioration afterward.A retrospective study in Japan showed that the ten-year accumulative incident risk of HCC was up to 4.3% in patients with diabetes mellitus or elevated fibrosis-4 index after SVR was achieved through interferon-based regimens [10].Consistently,we also observed some incident HCC cases.Our accumulative AIR of HCC was relatively lower than the previous reports [9,10].However,when the incidence of progression of liver disease was simultaneously calculated,the accumulative AIR of liver deterioration (HCC or progression of liver disease) was 2.73%.Another large-scale observational study also implied that the risk of HCC remained elevated for several years after SVR12 was achieved through an interferon-based treatment [11].The annual risk of HCC incidence was about 0.3% [11].In our study,the risk of HCC incidence was 0.66% in the first year after SVR24 and 0.93% in the second year,and no more cases were found in the remaining years which may due to limited sample size.However,progression of liver disease was still found in the third and fourth years.

    Previous studies [9-11]highlighted that patients with cirrhosis,diabetes or who are elderly have a higher risk of HCC incidence.In addition,cirrhosis is an independent risk factor of HCC incidence and disease progression.It was reported that patients with HCVinduced cirrhosis have an annual risk of 1% for HCC and 2% for disease progression [12].The present study compared the longterm prognosis between cirrhotic and non-cirrhotic patients.Although the incident risk was not significantly different in the two groups,an elevated incidence of liver deterioration (HCC or progression of liver disease) was noted in HCV-induced cirrhotic patients compared with non-cirrhotic ones.Several large trials analyzed the progression of liver disease in previously HCV-infected subjects and found that 1% ?14% of them have disease progression [11,13,14].HCV alters glucose metabolism and leads to insulin resistance,sequentially resulting in accelerated fibrogenesis [15].This phenomenon may sustain post SVR.Meanwhile,the hepatic stellate cells,which were reverted to quiescence after SVR,may be reactivated [16].We observed several cases of progression of liver disease.In addition,the incidence of progression of liver disease was correlated with hepatic stellate cells activity in cirrhotic patients.As advanced fibrosis or cirrhosis increases the risk of HCC incidence after HCV eradication [17],the incidence of HCC may increase as the follow-up period is extended.

    We have reviewed the latest studies on long-term follow-up of Chinese patients,and the follow-up period of our study is longer than these studies [18–20].Most studies [18,19]reported prognosis at SVR24.In the long-term follow-up with an average period of 4.3 years in“CCgenos”program,334 patients received interferon-based treatment and 71.1% of them achieved SVR24 after treatment [18].In their observation,the risk score of cirrhosis and HCC shifted towards lower among patients who achieved SVR24.The probability for treated patients to develop cirrhosis decreased from 29% to 4%after SVR24.A trend toward reduced probability of HCC progression was also implied from the study although no significance was found.Our long-term follow-up started in patients who achieved SVR24.Extremely low incidence of cirrhosis,decompensated complications and HCC were found in our study which is also consisting with previous publications [18,19].Another study followed 265 patients who achieved SVR24 for over 1931 person-years,which reported that the incidence of HCC was higher in patients with advanced fibrosis (F3-4) [19].Our study also proved that liver cirrhosis was a critical risk factor for HCC in patients who achieved SVR24.

    Notably,a previous study reported no recurrence of HCV infection in a cohort of 197 sustained responders [5].These responders experienced a follow-up period for at least 12 months to confirm their SVR and an extra median follow-up period of 17 months.In our cohort with SVR24,we observed no HCV relapse but some cases of HCV reinfection in the long-term follow-up.According to our retrospective review,we found that these patients had potential risks of reinfection (drug injection,risky sexual behavior,or multiple blood transfusions).The recurrent viral genotype in the patient with drug injection was 3b,consistent with our previous publication [20].

    Direct-acting antiviral agents (DAAs) application has increased the rate of SVR24 to more than 90%,even close to 100% in certain patients with certain regimens.However,it is still not clear as which regimen,PR or DAAs,would provide a better long-term prognosis [21,22].Interferon has a potential anti-tumor capacity.When therapeutic type I interferon is given,interferon pathways is activated,and the type II interferon from immunocytes is secreted.Previous studies proved that type II interferon directly inhibits cell growth,promotes apoptosis,stimulates the secretion of reactive oxygen species and perforin from natural killer cells and macrophages,and promotes T lymphocyte transformation into Th1 cell and CD8+CTL [23,24].Multiple mechanisms are associated with the anti-tumor effect of interferon.Although DAAs have been approved in most countries in recent years,its long-term follow-up data are still lacking.Most studies [21,22,25]focus on the SVR12 or short-term prognosis within 2 years after treatment.Reddy KR et al.[25]conducted an observational study on clinical trial recipients of daclatasvir-based regimens after SVR12 was achieved and it turned out that the SVR was durable in 99% of recipients.Progression of liver disease and new HCC were found in 15 and 23 patients respectively,indicating that the risk existed but it was infrequent.The result is consistent with ours.It implied that no matter which kind of antivirals was applied,prognosis is improved after viral eradication.We hope comparable follow-up data over 5 years provided more clear evidence.

    In conclusion,we reported the long-term prognosis of HCVinfected individuals who experienced a SVR24 after PR treatment.HCC event and progression of liver disease did exist in our cohort,but at a low rate.Cirrhotic patients were more vulnerable during treatment or post SVR.More cirrhotic patients would experience adjusted regimens compared with non-cirrhotic patients.Cirrhotic patients had a higher risk of poor prognosis after treatment.HCV recurrence was rare in responders with SVR24 who had corrected their risky behaviors.

    Acknowledgments

    We sincerely thank Rui-Chao Yu and Sanin Andres for their help in English revision.

    CRediT authorship contribution statement

    Yuan-Ji Ma:Formal analysis,Writing– original draft,Writing– review &editing.Ling-Yao Du:Data curation,Formal analysis,Writing– review &editing.Li-Bo Yan:Data curation and Validation.Juan Liao:Investigation.Xing Cheng:Resources.Wu-WeiXie:Project administration.Hong Tang:Conceptualization,Funding acquisition,Writing– review &editing.

    Funding

    This study was supported by the Research Project of Health Commission of Sichuan Province (No.17PJ006).

    Ethical approval

    This study was approved by the Ethics Committee of West China Hospital,Chengdu,China [Authorization number:2016 annual audit (91)].

    Competing interest

    No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    2021天堂中文幕一二区在线观| 亚洲熟妇中文字幕五十中出| 亚洲第一电影网av| 国产伦精品一区二区三区四那| 亚洲欧美日韩东京热| 青草久久国产| 2021天堂中文幕一二区在线观| 日韩高清综合在线| 日韩欧美国产一区二区入口| 久久久久久久久大av| 日韩精品中文字幕看吧| 在线播放无遮挡| 两人在一起打扑克的视频| 亚洲av熟女| 波野结衣二区三区在线| 99久国产av精品| 色精品久久人妻99蜜桃| 美女xxoo啪啪120秒动态图 | 亚洲自偷自拍三级| 久久精品夜夜夜夜夜久久蜜豆| 亚洲精品456在线播放app | 日本撒尿小便嘘嘘汇集6| 亚洲精品乱码久久久v下载方式| .国产精品久久| 熟女人妻精品中文字幕| 久久婷婷人人爽人人干人人爱| 真实男女啪啪啪动态图| 一区二区三区免费毛片| 2021天堂中文幕一二区在线观| 精品国内亚洲2022精品成人| 99国产精品一区二区蜜桃av| 99国产极品粉嫩在线观看| 九色国产91popny在线| 俄罗斯特黄特色一大片| 1000部很黄的大片| 成年人黄色毛片网站| 成人特级黄色片久久久久久久| 又爽又黄无遮挡网站| 精品久久国产蜜桃| 两个人的视频大全免费| 中文字幕人妻熟人妻熟丝袜美| 一个人观看的视频www高清免费观看| 18禁黄网站禁片免费观看直播| 免费av观看视频| 最近在线观看免费完整版| 高清日韩中文字幕在线| 婷婷亚洲欧美| 特大巨黑吊av在线直播| 黄色视频,在线免费观看| 91久久精品电影网| 免费在线观看日本一区| 亚洲最大成人手机在线| 久久精品夜夜夜夜夜久久蜜豆| 国产白丝娇喘喷水9色精品| 在线看三级毛片| 日本精品一区二区三区蜜桃| 亚洲精品日韩av片在线观看| 18+在线观看网站| 黄色视频,在线免费观看| 变态另类成人亚洲欧美熟女| 精品熟女少妇八av免费久了| 久久精品久久久久久噜噜老黄 | 脱女人内裤的视频| 美女cb高潮喷水在线观看| 桃色一区二区三区在线观看| 亚州av有码| 婷婷精品国产亚洲av| 观看免费一级毛片| 69人妻影院| 国产不卡一卡二| 欧美日本视频| 精品欧美国产一区二区三| 无遮挡黄片免费观看| 国产精品99久久久久久久久| 一级作爱视频免费观看| 国产私拍福利视频在线观看| 精品久久久久久久人妻蜜臀av| 国产成人aa在线观看| 亚州av有码| 国产高潮美女av| 欧美乱色亚洲激情| 国产又黄又爽又无遮挡在线| 欧美一区二区精品小视频在线| 亚洲美女黄片视频| 亚洲精品亚洲一区二区| 黄色配什么色好看| 成人国产综合亚洲| 一夜夜www| 亚洲性夜色夜夜综合| 九九热线精品视视频播放| 国产高清视频在线观看网站| 久久久成人免费电影| 国产精品久久久久久精品电影| 91av网一区二区| 午夜免费成人在线视频| 波多野结衣高清无吗| 欧美一区二区精品小视频在线| 91久久精品电影网| 人妻夜夜爽99麻豆av| 亚洲一区二区三区色噜噜| 亚洲一区二区三区不卡视频| 真人做人爱边吃奶动态| 亚洲三级黄色毛片| 九色国产91popny在线| 国产成人啪精品午夜网站| 久久精品国产99精品国产亚洲性色| 久久久久性生活片| 可以在线观看的亚洲视频| 午夜精品在线福利| 男人的好看免费观看在线视频| 一区二区三区免费毛片| 毛片女人毛片| 午夜精品久久久久久毛片777| 成年人黄色毛片网站| 国模一区二区三区四区视频| 亚洲精品影视一区二区三区av| 免费观看人在逋| 国产欧美日韩精品亚洲av| 亚州av有码| 他把我摸到了高潮在线观看| 噜噜噜噜噜久久久久久91| 俄罗斯特黄特色一大片| 久久人人爽人人爽人人片va | av天堂在线播放| 日韩欧美精品v在线| eeuss影院久久| 精华霜和精华液先用哪个| 少妇被粗大猛烈的视频| 国产精品,欧美在线| 亚洲熟妇熟女久久| a级毛片a级免费在线| 长腿黑丝高跟| 久久久久久久午夜电影| 90打野战视频偷拍视频| 老司机深夜福利视频在线观看| 欧美日韩瑟瑟在线播放| 国产乱人伦免费视频| 久久国产精品影院| 三级男女做爰猛烈吃奶摸视频| 精品一区二区三区视频在线观看免费| 三级国产精品欧美在线观看| 亚洲中文字幕一区二区三区有码在线看| 亚洲 欧美 日韩 在线 免费| 亚洲专区国产一区二区| 国产探花极品一区二区| 欧美绝顶高潮抽搐喷水| 国产av一区在线观看免费| 亚洲欧美精品综合久久99| 国产麻豆成人av免费视频| 女人被狂操c到高潮| 免费黄网站久久成人精品 | 国产精品久久久久久亚洲av鲁大| 最好的美女福利视频网| 久久精品国产亚洲av香蕉五月| 香蕉av资源在线| 天堂√8在线中文| 嫩草影院新地址| 国产亚洲精品久久久com| 一个人观看的视频www高清免费观看| 嫁个100分男人电影在线观看| 1024手机看黄色片| av女优亚洲男人天堂| 国产视频内射| 亚洲第一欧美日韩一区二区三区| 亚洲精品乱码久久久v下载方式| 国产精品电影一区二区三区| 内射极品少妇av片p| 又紧又爽又黄一区二区| 亚洲成人久久性| 91午夜精品亚洲一区二区三区 | 日韩欧美国产一区二区入口| 色在线成人网| 亚州av有码| a级毛片a级免费在线| 天天躁日日操中文字幕| 在现免费观看毛片| 美女 人体艺术 gogo| 中出人妻视频一区二区| 久久草成人影院| 蜜桃久久精品国产亚洲av| 乱码一卡2卡4卡精品| 婷婷丁香在线五月| 乱码一卡2卡4卡精品| 久久久久免费精品人妻一区二区| 在线观看66精品国产| 最好的美女福利视频网| av欧美777| 国产黄a三级三级三级人| 日韩欧美免费精品| 久久久久九九精品影院| 中文字幕精品亚洲无线码一区| 男人狂女人下面高潮的视频| 一卡2卡三卡四卡精品乱码亚洲| 久久伊人香网站| 好看av亚洲va欧美ⅴa在| 少妇熟女aⅴ在线视频| 亚洲中文字幕一区二区三区有码在线看| 亚洲精品亚洲一区二区| 欧美黑人欧美精品刺激| 欧美日韩乱码在线| 好男人在线观看高清免费视频| 特大巨黑吊av在线直播| a级一级毛片免费在线观看| 精品福利观看| 日本免费一区二区三区高清不卡| 国产精品av视频在线免费观看| 舔av片在线| 午夜老司机福利剧场| 日本一二三区视频观看| 精品日产1卡2卡| 欧美日韩国产亚洲二区| 三级国产精品欧美在线观看| 男人舔女人下体高潮全视频| 超碰av人人做人人爽久久| 日韩 亚洲 欧美在线| 精品人妻一区二区三区麻豆 | 国产三级在线视频| 日韩成人在线观看一区二区三区| 精品一区二区免费观看| 男女下面进入的视频免费午夜| a级毛片免费高清观看在线播放| 欧美在线一区亚洲| 欧美xxxx性猛交bbbb| 怎么达到女性高潮| 伦理电影大哥的女人| 久久精品人妻少妇| 国产一区二区在线观看日韩| 亚洲av日韩精品久久久久久密| 老鸭窝网址在线观看| 久久99热6这里只有精品| 真实男女啪啪啪动态图| 亚洲av二区三区四区| 美女大奶头视频| 色综合站精品国产| 中出人妻视频一区二区| 亚洲中文日韩欧美视频| 永久网站在线| 我的女老师完整版在线观看| 欧美成人性av电影在线观看| 一级作爱视频免费观看| 老司机福利观看| 看黄色毛片网站| 国产黄片美女视频| 亚洲精品在线观看二区| 色综合亚洲欧美另类图片| 18禁在线播放成人免费| 狠狠狠狠99中文字幕| 两个人的视频大全免费| 亚洲中文字幕日韩| 最新中文字幕久久久久| 国内毛片毛片毛片毛片毛片| 精品一区二区三区视频在线| 欧美成人免费av一区二区三区| 观看免费一级毛片| 成人高潮视频无遮挡免费网站| 久久香蕉精品热| 亚洲成人精品中文字幕电影| 欧美性感艳星| 成人av在线播放网站| 高清在线国产一区| 国产激情偷乱视频一区二区| 国产午夜福利久久久久久| 久久这里只有精品中国| 一夜夜www| 99久久精品国产亚洲精品| 国产av麻豆久久久久久久| 黄色日韩在线| 久久精品国产自在天天线| 亚洲最大成人av| 青草久久国产| 99久久成人亚洲精品观看| 色5月婷婷丁香| 每晚都被弄得嗷嗷叫到高潮| 久久久久久久久大av| 最近中文字幕高清免费大全6 | 久久精品综合一区二区三区| 男人的好看免费观看在线视频| 亚洲男人的天堂狠狠| 欧美乱色亚洲激情| 国产精品久久久久久亚洲av鲁大| 国产一区二区在线av高清观看| 欧美色视频一区免费| 99热这里只有是精品50| 99视频精品全部免费 在线| 他把我摸到了高潮在线观看| 真人一进一出gif抽搐免费| 久久人妻av系列| 熟女电影av网| 国产精品,欧美在线| 中国美女看黄片| 99热这里只有精品一区| 一个人看视频在线观看www免费| 日韩欧美国产一区二区入口| 变态另类丝袜制服| 久久久久九九精品影院| 又爽又黄a免费视频| 国产毛片a区久久久久| 精华霜和精华液先用哪个| 嫩草影院精品99| 欧美3d第一页| 色综合婷婷激情| 国产极品精品免费视频能看的| 久久中文看片网| 国产精品久久久久久人妻精品电影| 久久久国产成人免费| 观看免费一级毛片| 99视频精品全部免费 在线| 美女高潮喷水抽搐中文字幕| 啪啪无遮挡十八禁网站| 久久精品国产亚洲av天美| 老司机深夜福利视频在线观看| 精华霜和精华液先用哪个| 嫩草影院新地址| 成年女人毛片免费观看观看9| 老司机深夜福利视频在线观看| h日本视频在线播放| 久久国产乱子伦精品免费另类| 欧美一区二区国产精品久久精品| 99在线视频只有这里精品首页| 国产探花在线观看一区二区| 亚洲第一区二区三区不卡| 久久99热这里只有精品18| 色精品久久人妻99蜜桃| 欧美极品一区二区三区四区| 国产探花极品一区二区| 色在线成人网| 最近中文字幕高清免费大全6 | 99国产综合亚洲精品| 男人狂女人下面高潮的视频| 欧美高清成人免费视频www| 91av网一区二区| 老鸭窝网址在线观看| 欧美又色又爽又黄视频| 免费大片18禁| 久久精品国产99精品国产亚洲性色| 国内精品一区二区在线观看| 久久精品夜夜夜夜夜久久蜜豆| 亚洲国产精品成人综合色| 国产av一区在线观看免费| 国产精品一区二区性色av| 一二三四社区在线视频社区8| 精品无人区乱码1区二区| 中文资源天堂在线| 中文字幕人成人乱码亚洲影| 最后的刺客免费高清国语| 一本精品99久久精品77| 999久久久精品免费观看国产| 色吧在线观看| 日韩欧美精品免费久久 | 午夜免费成人在线视频| 亚洲七黄色美女视频| 精品99又大又爽又粗少妇毛片 | 看十八女毛片水多多多| 少妇丰满av| 亚洲精品久久国产高清桃花| 免费观看精品视频网站| 国产av在哪里看| 一个人观看的视频www高清免费观看| 最近最新中文字幕大全电影3| 国产亚洲精品久久久久久毛片| 亚洲内射少妇av| 少妇人妻精品综合一区二区 | 亚洲不卡免费看| 在线天堂最新版资源| 国产精品自产拍在线观看55亚洲| 午夜福利成人在线免费观看| av天堂中文字幕网| 丰满人妻一区二区三区视频av| 免费在线观看亚洲国产| 99久久九九国产精品国产免费| 亚洲熟妇熟女久久| 成年女人毛片免费观看观看9| 欧美最新免费一区二区三区 | 天堂√8在线中文| 日韩亚洲欧美综合| 欧美日本视频| 一a级毛片在线观看| 日本 欧美在线| 一级黄片播放器| 国产精品乱码一区二三区的特点| 日本与韩国留学比较| 亚洲性夜色夜夜综合| 欧美国产日韩亚洲一区| 国语自产精品视频在线第100页| 免费高清视频大片| 国产v大片淫在线免费观看| 午夜两性在线视频| av在线天堂中文字幕| 精品人妻一区二区三区麻豆 | 亚洲无线在线观看| 成人鲁丝片一二三区免费| 伦理电影大哥的女人| 宅男免费午夜| 成年人黄色毛片网站| 丰满人妻熟妇乱又伦精品不卡| 婷婷精品国产亚洲av| 哪里可以看免费的av片| 少妇被粗大猛烈的视频| 久久九九热精品免费| 最近最新中文字幕大全电影3| 三级男女做爰猛烈吃奶摸视频| 国产精品日韩av在线免费观看| 久久精品综合一区二区三区| 桃色一区二区三区在线观看| 亚洲专区国产一区二区| 97超视频在线观看视频| bbb黄色大片| 亚洲va日本ⅴa欧美va伊人久久| 亚洲综合色惰| 午夜免费激情av| 免费观看精品视频网站| 国产免费一级a男人的天堂| 国产黄a三级三级三级人| 99久国产av精品| 欧美日韩综合久久久久久 | 午夜精品一区二区三区免费看| 精品一区二区三区人妻视频| 99热只有精品国产| 国产真实乱freesex| 国产伦在线观看视频一区| 男女做爰动态图高潮gif福利片| 日本一二三区视频观看| 国产熟女xx| 免费看a级黄色片| 国产精品女同一区二区软件 | 深夜精品福利| 夜夜夜夜夜久久久久| 黄色丝袜av网址大全| 亚洲专区中文字幕在线| 中文字幕熟女人妻在线| 男人狂女人下面高潮的视频| 尤物成人国产欧美一区二区三区| 中文字幕av在线有码专区| 真人做人爱边吃奶动态| 久久久久久久亚洲中文字幕 | 在线看三级毛片| 日本一二三区视频观看| 最近在线观看免费完整版| 亚洲不卡免费看| av天堂中文字幕网| 淫秽高清视频在线观看| 国产69精品久久久久777片| 又黄又爽又免费观看的视频| 国产精品一及| а√天堂www在线а√下载| 亚洲精品乱码久久久v下载方式| 亚洲精品在线美女| 亚洲av美国av| bbb黄色大片| 国产探花极品一区二区| 国产亚洲精品久久久久久毛片| 久久精品国产自在天天线| 成人无遮挡网站| 亚洲av成人精品一区久久| 亚洲三级黄色毛片| 国产淫片久久久久久久久 | 免费在线观看日本一区| 国产高清视频在线播放一区| 欧美激情在线99| 又爽又黄a免费视频| 自拍偷自拍亚洲精品老妇| 久久天躁狠狠躁夜夜2o2o| 蜜桃久久精品国产亚洲av| 亚洲专区国产一区二区| 日韩欧美三级三区| 一进一出抽搐动态| 一个人看的www免费观看视频| 有码 亚洲区| 成熟少妇高潮喷水视频| 成人高潮视频无遮挡免费网站| 村上凉子中文字幕在线| 一级毛片久久久久久久久女| www.熟女人妻精品国产| 亚洲真实伦在线观看| 色精品久久人妻99蜜桃| 日日摸夜夜添夜夜添小说| 日韩欧美 国产精品| 日本 欧美在线| av专区在线播放| 黄色女人牲交| 热99re8久久精品国产| 在线天堂最新版资源| 亚洲无线在线观看| 最近最新中文字幕大全电影3| 亚洲国产高清在线一区二区三| 国产欧美日韩精品亚洲av| 免费看日本二区| 12—13女人毛片做爰片一| 一个人观看的视频www高清免费观看| 免费在线观看日本一区| 中文字幕人成人乱码亚洲影| 真人一进一出gif抽搐免费| 欧美精品啪啪一区二区三区| 欧美精品国产亚洲| 国内久久婷婷六月综合欲色啪| 999久久久精品免费观看国产| 日本免费a在线| 久久国产精品人妻蜜桃| av国产免费在线观看| 69av精品久久久久久| 国产综合懂色| 精华霜和精华液先用哪个| 给我免费播放毛片高清在线观看| 人妻制服诱惑在线中文字幕| 丰满人妻一区二区三区视频av| 亚洲av不卡在线观看| 一区二区三区高清视频在线| 91久久精品国产一区二区成人| 国产精品野战在线观看| 男女做爰动态图高潮gif福利片| 精品熟女少妇八av免费久了| 小蜜桃在线观看免费完整版高清| 日韩中字成人| 国产真实乱freesex| 亚洲色图av天堂| 国产精品三级大全| 精品99又大又爽又粗少妇毛片 | 国产伦一二天堂av在线观看| 日韩欧美三级三区| 首页视频小说图片口味搜索| 亚洲电影在线观看av| 91久久精品国产一区二区成人| 99热这里只有是精品50| 五月伊人婷婷丁香| 能在线免费观看的黄片| 亚洲中文字幕一区二区三区有码在线看| 亚洲七黄色美女视频| 91在线观看av| 波多野结衣高清作品| www.熟女人妻精品国产| 午夜免费成人在线视频| 精品一区二区三区视频在线| 国语自产精品视频在线第100页| 欧美性感艳星| 淫妇啪啪啪对白视频| avwww免费| 桃色一区二区三区在线观看| 我的老师免费观看完整版| 色播亚洲综合网| 色5月婷婷丁香| 亚洲18禁久久av| 一本精品99久久精品77| 亚洲成人中文字幕在线播放| 国产精品美女特级片免费视频播放器| 久久国产精品影院| 国产精品久久久久久人妻精品电影| 麻豆一二三区av精品| 九色成人免费人妻av| 成年免费大片在线观看| 国产乱人视频| 女人十人毛片免费观看3o分钟| 国产综合懂色| 人人妻人人澡欧美一区二区| 成人性生交大片免费视频hd| 中文字幕高清在线视频| www.色视频.com| 蜜桃久久精品国产亚洲av| av天堂在线播放| 熟女人妻精品中文字幕| av天堂中文字幕网| 国产高清有码在线观看视频| 少妇的逼水好多| 我的女老师完整版在线观看| 久久久国产成人精品二区| 久久精品人妻少妇| 麻豆国产av国片精品| 国产免费一级a男人的天堂| 国产精品久久视频播放| 黄色日韩在线| 亚洲av电影在线进入| 18+在线观看网站| 亚洲国产高清在线一区二区三| 免费搜索国产男女视频| 男女那种视频在线观看| 久久久久久久久久黄片| 久久久久精品国产欧美久久久| 久久精品国产自在天天线| 简卡轻食公司| 国产极品精品免费视频能看的| 男人的好看免费观看在线视频| 波野结衣二区三区在线| 亚洲黑人精品在线| 国产精品人妻久久久久久| 九九热线精品视视频播放| 在线播放无遮挡| 十八禁网站免费在线| av黄色大香蕉| 亚洲自拍偷在线| 男人狂女人下面高潮的视频| 国产男靠女视频免费网站| 99热这里只有是精品在线观看 | 我要看日韩黄色一级片| 真实男女啪啪啪动态图| 免费电影在线观看免费观看| www.熟女人妻精品国产| 国产精品一及| 欧美潮喷喷水| 亚洲av成人av| 亚洲av中文字字幕乱码综合| 亚洲内射少妇av| 色综合婷婷激情| 国产高清视频在线观看网站| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 在线观看免费视频日本深夜| 亚洲精品久久国产高清桃花| 日韩中文字幕欧美一区二区| 青草久久国产| 国产精品综合久久久久久久免费| 麻豆成人午夜福利视频| 青草久久国产| 欧美三级亚洲精品| 欧美xxxx性猛交bbbb| 亚洲精品一区av在线观看| 老司机午夜十八禁免费视频| 久久人人精品亚洲av|